Skip to content

EyePoint, Inc. EYPT Change in Other Liabilities

Change in Other Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
$48.75M+498%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$69K-201%
LQD
Liquidia CorporationLQDA
$873K
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$55.6M+292,747%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's change in other liabilities?
EyePoint, Inc. (EYPT) reported change in other liabilities of -$6K in Q1 2026.
What does change in other liabilities mean?
Change in miscellaneous liabilities affecting operating cash flow.